Impact of Adjuvant Fractionated Stereotactic Radiotherapy Dose on Local Control of Brain Metastases

Overview

Journal J Neurooncol

Publisher Springer

Date 2019 Oct 14

PMID 31606876

Citations 7

Authors

Hima B Musunuru

Jacob S Witt

Poonam Yadav

David M Francis

Aleksandra Kuczmarska-Haas

Zacariah E Labby

Michael F Bassetti

Steven P Howard

Andrew M Baschnagel

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to determine whether a higher biological effective dose (BED) would result in improved local control in patients treated with fractionated stereotactic radiotherapy (FSRT) for their resected brain metastases.

Methods: Patients with newly diagnosed brain metastases without previous brain radiotherapy were retrospectively reviewed. Patients underwent surgical resection of at least one brain metastasis and were treated with adjuvant FSRT, delivering 25-36 Gy in 5-6 fractions. Outcomes were computed using Kaplan-Meier survival analysis and univariate analysis.

Results: Fifty-four patients with 63 post-operative cavities were included. Median follow-up was 16 months (3-60). Median metastasis size at diagnosis was 2.9 cm (0.6-8.1) and median planning target volume was 19.7 cm (6.3-68.1). Two-year local control (LC) was 83%. When stratified by dose, 2 years LC rate was 95.1% in those treated with 30-36 Gy in 5-6 fractions (BED of 48-57.6 Gy) versus 59.1% lesions treated with 25 Gy in 5 fractions (BED of 37.5 Gy) (p < 0.001). LC was not associated with resection cavity size. One year overall survival was 68.7%, and was independent of BED. Symptomatic radiation necrosis occurred in 7.9% of patients and was not associated with dose.

Conclusion: In the post-operative setting, high-dose FSRT (BED > 37.5 Gy) were associated with a significantly higher rate of LC compared to lower BED regimens. Overall, 25 Gy in 5 fractions is not an adequate dose to control microscopic disease. If selecting a 5-fraction regimen, 30 Gy in five fractions appears to provide excellent tumor bed control.

Citing Articles

Leveraging radiomics and machine learning to differentiate radiation necrosis from recurrence in patients with brain metastases.

Basree M, Li C, Um H, Bui A, Liu M, Ahmed A J Neurooncol. 2024; 168(2):307-316.

PMID: 38689115 DOI: 10.1007/s11060-024-04669-4.

Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiosurgery (SRS) to the resection cavity of brain metastases after surgical resection (SATURNUS): study protocol for a randomized phase III trial.

Waltenberger M, Bernhardt D, Diehl C, Gempt J, Meyer B, Straube C BMC Cancer. 2023; 23(1):709.

PMID: 37516835 PMC: 10385881. DOI: 10.1186/s12885-023-11202-9.

Pretreatment lymphocyte-to-monocyte ratio as a prognostic factor and influence on dose-effect in fractionated stereotactic radiotherapy for oligometastatic brain metastases in non-small cell lung cancer patients.

Chen T, Tang M, Zhou Y, Wang Z, Li S, Wang H Front Oncol. 2023; 13:1216852.

PMID: 37456254 PMC: 10348423. DOI: 10.3389/fonc.2023.1216852.

Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases.

Tonse R, Tom M, Mehta M, Ahluwalia M, Kotecha R Cancers (Basel). 2021; 13(15).

PMID: 34359583 PMC: 8345095. DOI: 10.3390/cancers13153682.

Outcome comparison of patients who develop leptomeningeal disease or distant brain recurrence after brain metastases resection cavity radiosurgery.

Teyateeti A, Brown P, Mahajan A, Laack N, Pollock B Neurooncol Adv. 2021; 3(1):vdab036.

PMID: 33860228 PMC: 8034660. DOI: 10.1093/noajnl/vdab036.

References

Chang E, Wefel J, Hess K, Allen P, Lang F, Kornguth D . Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009; 10(11):1037-44. DOI: 10.1016/S1470-2045(09)70263-3. View

Abuodeh Y, Ahmed K, Naghavi A, Venkat P, Sarangkasiri S, Johnstone P . Postoperative Stereotactic Radiosurgery Using 5-Gy × 5 Sessions in the Management of Brain Metastases. World Neurosurg. 2016; 90:58-65. DOI: 10.1016/j.wneu.2016.02.007. View

Brown P, Jaeckle K, Ballman K, Farace E, Cerhan J, Anderson S . Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. 2016; 316(4):401-409. PMC: 5313044. DOI: 10.1001/jama.2016.9839. View

Andrews D, Scott C, Sperduto P, Flanders A, Gaspar L, Schell M . Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004; 363(9422):1665-72. DOI: 10.1016/S0140-6736(04)16250-8. View

Eaton B, LaRiviere M, La Riviere M, Kim S, Prabhu R, Patel K . Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. J Neurooncol. 2015; 123(1):103-11. DOI: 10.1007/s11060-015-1767-4. View

Minniti G, Scaringi C, Paolini S, Lanzetta G, Romano A, Cicone F . Single-Fraction Versus Multifraction (3 × 9 Gy) Stereotactic Radiosurgery for Large (>2 cm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain Necrosis. Int J Radiat Oncol Biol Phys. 2016; 95(4):1142-8. DOI: 10.1016/j.ijrobp.2016.03.013. View

Sittenfeld S, Suh J, Murphy E, Yu J, Chao S . Contemporary Management of 1-4 Brain Metastases. Front Oncol. 2018; 8:385. PMC: 6165904. DOI: 10.3389/fonc.2018.00385. View

Mahajan A, Ahmed S, McAleer M, Weinberg J, Li J, Brown P . Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017; 18(8):1040-1048. PMC: 5560102. DOI: 10.1016/S1470-2045(17)30414-X. View

Combs S, Bilger A, Diehl C, Bretzinger E, Lorenz H, Oehlke O . Multicenter analysis of stereotactic radiotherapy of the resection cavity in patients with brain metastases. Cancer Med. 2018; 7(6):2319-2327. PMC: 6010760. DOI: 10.1002/cam4.1477. View

10.

Brown P, Ballman K, Cerhan J, Anderson S, Carrero X, Whitton A . Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017; 18(8):1049-1060. PMC: 5568757. DOI: 10.1016/S1470-2045(17)30441-2. View

11.

Minniti G, Esposito V, Clarke E, Scaringi C, Lanzetta G, Salvati M . Multidose stereotactic radiosurgery (9 Gy × 3) of the postoperative resection cavity for treatment of large brain metastases. Int J Radiat Oncol Biol Phys. 2013; 86(4):623-9. DOI: 10.1016/j.ijrobp.2013.03.037. View

12.

Soon Y, Tham I, Lim K, Koh W, Lu J . Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases. Cochrane Database Syst Rev. 2014; (3):CD009454. PMC: 6457788. DOI: 10.1002/14651858.CD009454.pub2. View

13.

Soliman H, Ruschin M, Angelov L, Brown P, Chiang V, Kirkpatrick J . Consensus Contouring Guidelines for Postoperative Completely Resected Cavity Stereotactic Radiosurgery for Brain Metastases. Int J Radiat Oncol Biol Phys. 2017; 100(2):436-442. DOI: 10.1016/j.ijrobp.2017.09.047. View

14.

Kumar A, Miller J, Hoffer S, Mansur D, Coffey M, Lo S . Postoperative hypofractionated stereotactic brain radiation (HSRT) for resected brain metastases: improved local control with higher BED. J Neurooncol. 2018; 139(2):449-454. DOI: 10.1007/s11060-018-2885-6. View

15.

Rajakesari S, Arvold N, Jimenez R, Christianson L, Horvath M, Claus E . Local control after fractionated stereotactic radiation therapy for brain metastases. J Neurooncol. 2014; 120(2):339-46. DOI: 10.1007/s11060-014-1556-5. View

16.

Lockney N, Wang D, Gutin P, Brennan C, Tabar V, Ballangrud A . Clinical outcomes of patients with limited brain metastases treated with hypofractionated (5×6Gy) conformal radiotherapy. Radiother Oncol. 2017; 123(2):203-208. PMC: 5477478. DOI: 10.1016/j.radonc.2017.03.018. View